These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 30864023)

  • 1. Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options.
    Hewitt RJ; Maher TM
    Drugs Aging; 2019 Jun; 36(6):485-492. PubMed ID: 30864023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and immunity in IPF pathogenesis and treatment.
    Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
    Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.
    Pardo A; Selman M
    Ann Am Thorac Soc; 2016 Dec; 13 Suppl 5():S417-S421. PubMed ID: 28005427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
    Rangarajan S; Locy ML; Luckhardt TR; Thannickal VJ
    Drugs; 2016 Mar; 76(3):291-300. PubMed ID: 26729185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis.
    Li Y; Jiang C; Zhu W; Lu S; Yu H; Meng L
    Sci Prog; 2024; 107(2):368504241247402. PubMed ID: 38651330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrotic extracellular matrix activates a profibrotic positive feedback loop.
    Parker MW; Rossi D; Peterson M; Smith K; Sikström K; White ES; Connett JE; Henke CA; Larsson O; Bitterman PB
    J Clin Invest; 2014 Apr; 124(4):1622-35. PubMed ID: 24590289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'.
    Tomos IP; Tzouvelekis A; Aidinis V; Manali ED; Bouros E; Bouros D; Papiris SA
    Expert Rev Respir Med; 2017 Apr; 11(4):299-309. PubMed ID: 28274188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts.
    Monaghan-Benson E; Wittchen ES; Doerschuk CM; Burridge K
    Mol Biol Cell; 2018 Sep; 29(18):2165-2175. PubMed ID: 29995590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
    Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
    Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel therapies for idiopathic pulmonary fibrosis].
    Wand O; Kremer MR
    Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
    Ahluwalia N; Shea BS; Tager AM
    Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
    Bonella F; Stowasser S; Wollin L
    Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Strategies for Idiopathic Pulmonary Fibrosis - Thriving Present and Promising Tomorrow.
    Gupta N; Paryani M; Patel S; Bariya A; Srivastava A; Pathak Y; Butani S
    J Clin Pharmacol; 2024 Jul; 64(7):779-798. PubMed ID: 38346921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.